United Therapeutics Announces Additional Results From FREEDOM-EV Study Showing The Hemodynamic And Risk Status Reduction Benefits Of Orenitram Treatment In Patients With Pulmonary Arterial Hypertension - Herald-Mail Media
[unable to retrieve full-text content] Progress on Cardiovascular Disease Care in the U.S. Has Stalled Despite Treatment Advances, New Report Finds The Harvard Crimson
Comments
Post a Comment